167 related articles for article (PubMed ID: 35655408)
21. Detection of MYCN amplification using blood plasma: noninvasive therapy evaluation and prediction of prognosis in neuroblastoma.
Kojima M; Hiyama E; Fukuba I; Yamaoka E; Ueda Y; Onitake Y; Kurihara S; Sueda T
Pediatr Surg Int; 2013 Nov; 29(11):1139-45. PubMed ID: 24022278
[TBL] [Abstract][Full Text] [Related]
22. Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma.
Chicard M; Boyault S; Colmet Daage L; Richer W; Gentien D; Pierron G; Lapouble E; Bellini A; Clement N; Iacono I; Bréjon S; Carrere M; Reyes C; Hocking T; Bernard V; Peuchmaur M; Corradini N; Faure-Conter C; Coze C; Plantaz D; Defachelles AS; Thebaud E; Gambart M; Millot F; Valteau-Couanet D; Michon J; Puisieux A; Delattre O; Combaret V; Schleiermacher G
Clin Cancer Res; 2016 Nov; 22(22):5564-5573. PubMed ID: 27440268
[TBL] [Abstract][Full Text] [Related]
23. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
[TBL] [Abstract][Full Text] [Related]
24. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
[TBL] [Abstract][Full Text] [Related]
25. Bile cell‑free DNA as a novel and powerful liquid biopsy for detecting somatic variants in biliary tract cancer.
Shen N; Zhang D; Yin L; Qiu Y; Liu J; Yu W; Fu X; Zhu B; Xu X; Duan A; Chen Z; Wang X; Cao X; Zhao T; Zhou Z; Yu L; Qin H; Fang Z; Li JY; Liu Y; Xiong L; Yuan B; Li F; Zhang Y
Oncol Rep; 2019 Aug; 42(2):549-560. PubMed ID: 31173267
[TBL] [Abstract][Full Text] [Related]
26. A Case-Control Study by ddPCR of ALU 260/111 and LINE-1 266/97 Copy Number Ratio in Circulating Cell-Free DNA in Plasma Revealed LINE-1 266/97 as a Potential Biomarker for Early Breast Cancer Detection.
Bortul M; Giudici F; Tierno D; Generali D; Scomersi S; Grassi G; Bottin C; Cappelletti MR; Zanconati F; Scaggiante B
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239866
[TBL] [Abstract][Full Text] [Related]
27. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
Cao Y; Jin Y; Yu J; Wang J; Qiu Y; Duan X; Ye Y; Cheng Y; Dong L; Feng X; Wang D; Li Z; Tian X; Wang H; Yan J; Zhao Q
Oncotarget; 2017 Jul; 8(30):49689-49701. PubMed ID: 28591696
[TBL] [Abstract][Full Text] [Related]
28. A prospective evaluation of liquid biopsy for detecting MYCN amplification in neuroblastoma patients.
Iehara T; Yagyu S; Gotoh T; Ouchi K; Yoshida H; Miyachi M; Kikuchi K; Sugimoto T; Hosoi H
Jpn J Clin Oncol; 2019 Aug; 49(8):743-748. PubMed ID: 31053863
[TBL] [Abstract][Full Text] [Related]
29. Denaturation-Enhanced Droplet Digital PCR for Liquid Biopsies.
Fitarelli-Kiehl M; Yu F; Ashtaputre R; Leong KW; Ladas I; Supplee J; Paweletz C; Mitra D; Schoenfeld JD; Parangi S; Makrigiorgos GM
Clin Chem; 2018 Dec; 64(12):1762-1771. PubMed ID: 30274976
[TBL] [Abstract][Full Text] [Related]
30. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
Marrano P; Irwin MS; Thorner PS
Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
[TBL] [Abstract][Full Text] [Related]
31. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY
PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795
[TBL] [Abstract][Full Text] [Related]
32. Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.
Kumps C; Fieuw A; Mestdagh P; Menten B; Lefever S; Pattyn F; De Brouwer S; Sante T; Schulte JH; Schramm A; Van Roy N; Van Maerken T; Noguera R; Combaret V; Devalck C; Westermann F; Laureys G; Eggert A; Vandesompele J; De Preter K; Speleman F
PLoS One; 2013; 8(1):e52321. PubMed ID: 23308108
[TBL] [Abstract][Full Text] [Related]
33. Copy number status and mutation analyses of anaplastic lymphoma kinase (ALK) gene in 90 sporadic neuroblastoma tumors.
Bagci O; Tumer S; Olgun N; Altungoz O
Cancer Lett; 2012 Apr; 317(1):72-7. PubMed ID: 22085494
[TBL] [Abstract][Full Text] [Related]
34. Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients.
Kaneko A; Kanemaru H; Kajihara I; Mijiddorj T; Miyauchi H; Kuriyama H; Kimura T; Sawamura S; Makino K; Miyashita A; Aoi J; Makino T; Masuguchi S; Fukushima S; Ihn H
J Dermatol Sci; 2021 Jun; 102(3):158-166. PubMed ID: 34049769
[TBL] [Abstract][Full Text] [Related]
35. Comparison of different techniques for the detection of genetic risk-identifying chromosomal gains and losses in neuroblastoma.
Villamón E; Piqueras M; Mackintosh C; Alonso J; de Alava E; Navarro S; Noguera R
Virchows Arch; 2008 Jul; 453(1):47-55. PubMed ID: 18574593
[TBL] [Abstract][Full Text] [Related]
36. High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene.
Carén H; Erichsen J; Olsson L; Enerbäck C; Sjöberg RM; Abrahamsson J; Kogner P; Martinsson T
BMC Genomics; 2008 Jul; 9():353. PubMed ID: 18664255
[TBL] [Abstract][Full Text] [Related]
37. The Detection of Genetic Parameters for Prognostic Stratification of Neuroblastoma Using Multiplex Ligation-Dependent Probe Amplification Technique.
Tumer S; Altungoz O; Bagci O; Olgun HN
Genet Test Mol Biomarkers; 2016 Feb; 20(2):74-80. PubMed ID: 26790040
[TBL] [Abstract][Full Text] [Related]
38. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
[TBL] [Abstract][Full Text] [Related]
39. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
[TBL] [Abstract][Full Text] [Related]
40. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
Aygun N; Altungoz O
Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]